Hepion Pharmaceuticals Inc (HEPA)
HEALTH CARE:
PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in preclinical studies. Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing Phase 2a NASH program, Hepion will use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space.
| Market Cap | 141.017 Million | Shares Outstanding | 76.225 Million | Avg 30-day Volume | 4.244 Million | ||
| P/E Ratio | Dividend Yield | EPS | |||||
| Price/Sales | Debt to Equity | EBITDA | |||||
| Price to Book Value | 0.0 | Forward PE | -3.88 | Enterprise Value | |||
| Total Cash | Current Debt | Gross Profit | |||||
| BETA | 0.99912 | 52-week High/Low | 4.83 / 1.26 | Next Earnings Date | Price to Cash FLow (P/CF) | -9999999.0 | |
| Data provided by IEX Cloud | |||||||
| Q4 2020 | All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|---|---|---|---|---|---|
| In top 10: | 0 | 0 | 0 (0.0%) | 0 (0.0%) | ||
| Funds Holding: | 38 | 21 | 80.95% | 13 (0.78%) | 8 (0.5%) | 62.5% |
| 13F shares: | 5.464 Million | 268.014 Thousand | 1938.58% | 1.3 Million | 149.852 Thousand | 767.4% |
| % Ownership | 17.0606 | 2.9696 | 474.51% | 4.0587 | 1.6604 | 144.44% |
| New Positions: | 22 | 8 | 175.0% | 8 | 5 | 60.0% |
| Increased Positions | 7 | 4 | 75.0% | 3 | 1 | 200.0% |
| Closed Positions | 5 | 4 | 25.0% | 3 | 1 | 200.0% |
| Reduced Positions | 3 | 2 | 50.0% | 1 | 1 | 0.0% |
| Total Calls | 216.629 Thousand | 45.7 Thousand | 374.02% | 46.7 Thousand | 28.2 Thousand | 65.6% |
| Total Puts | 156.812 Thousand | 591 | 26433.33% | 26.419 Thousand | 591 | 4370.22% |
| PUT/CALL Ratio | 0.72 | 0.01 | 7100.0% | 0.57 | 0.02 | 2750.0% |
| 1 hedge funds and active managers as identified by whalewisdom.com through public filings. | ||||||
- Here are the 10 most popular hedge fund managers in WhaleWisdom. Investors react to every move they make. 03/26/2021
- Long-time Wayfair insider bought $13.6M of W on the open market. Growth to continue post-pandemic? 03/09/2021
- Hedge fund XN was one of 2020's largest new funds. Gaurav Kapadia is off to an impressive start. 03/05/2021
- While investors party like its 1999, Insiders are selling stock like there's no tomorrow. Is a crash imminent? 02/23/2021
- Hedge Funds Flock To Sea’s Stock For Future Growth Opportunities 04/12/2021
- Hedge Fund's Are Moving Into Spotify 04/05/2021
- CrowdStrike's Stock Soars Amid Global Pandemic 03/29/2021
- PayPal's Continues Upward Climb As Hedge Funds Pile In 03/22/2021
- Hedge Funds Are Still Upbeat On Slumping Qualcomm 03/15/2021
- TripAdvisor Moves Beyond Pandemic Lows 03/08/2021
